Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and rising geriatric population base. According to U.S. National Cancer Institute GBM is considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma and shows rapid growth rate of benign cells in the organ. Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
The GBM treatment market on the basis of therapy is segmented into temozolomide, bevacozumab, and carmustine. Temozolomide accounted for the largest market share in 2014 with respect to revenue owing to the advantages offered by the drug which include delayed progression without impacting on quality of life and comparatively less adverse effects of the molecule. Moreover, methylated or alkylated DNA in the structural anomalies of the drug produces a better therapeutic efficacy thus leading to higher preference of the drug over the other segments. On the contrary, pipeline drugs under phase III trials such as Rindopepimut (CDX-110) and DCVax are expected to be the fastest growing segment over the forecast period as a consequence of observation of adverse events in adult patient base with the use of the available drug options.
Geographically, the GBM treatment market is segmented into North America, Europe, Asia Pacific, Latin America and MEA. North America held substantial market share in 2014. The major factors attributing towards the high share of this region include biopharmaceutical research, medicine development, increasing incidences of the central nervous system cancers in the geriatric population. This region leads the market owing to governmental and non-governmental support and the presence of vaccine products that are under the clinical phases for trials for treatment of glioblastoma multiforme. Brain Tumor Foundation of Canada, National Brain Tumor Society, and American Brain Tumor Association are the health organizations involved in raising awareness about GBM thus leading to growth of the market in the coming seven years. Presence of manufactures for the drugs used for treatment of GBM also contributed to the expansion of the glioblastoma multiforme treatment market in North America. Asia Pacific is expected to be the fastest growing segment over the forecast period as a result of updation in healthcare infrastructure and rising awareness of GBM. Furthermore, extensive use of genomic profiling in bioinformatics technology by the R&D firms in this region is expected to enhance the treatment of nervous carcinoma by revealing the new drug targets.
The prominent players in this market are Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., and F. Hoffmann-Le Roche AG. The key market players are adopting competitive marketing strategies to maintain their market share. These strategies include development of biological drugs that reduce the presence of side effects in the patients that are caused due to the consumption of the immunosuppresants and chemotherapeutic agents with multiple therapies. Involvement of microarray based gene profiling and gene sequencing techniques also tends to boost up the GBM treatment market by developing novel drug moieties. The other strategies adopted by the market players are collaboration with the diagnostic laboratories in order to raise awareness level of the population regarding the availability of treatment options for the invasive disease.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.